Health Care & Life Sciences » Pharmaceuticals | Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. Cl A | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
272,812.00
189,618.00
142,669.00
81,708.00
116,937.00
282,368
Depreciation, Depletion & Amortization
11,729.00
12,331.00
11,630.00
11,260.00
14,617.00
14,223
Other Funds
-
-
-
-
15,058.00
189,647
Funds from Operations
237,671.00
125,468.00
68,688.00
20,415.00
77,775.00
78,498
Changes in Working Capital
35,184.00
30,100.00
37,639.00
5,018.00
21,788.00
7,616
Net Operating Cash Flow
272,855.00
155,568.00
106,327.00
25,433.00
99,563.00
70,882
Capital Expenditures
9,592.00
3,538.00
4,049.00
104,206.00
4,211.00
Sale of Fixed Assets & Businesses
-
-
147.00
225.00
135.00
Purchase/Sale of Investments
91,841.00
53,031.00
5,251.00
73,693.00
155,536.00
Net Investing Cash Flow
101,433.00
56,569.00
9,153.00
177,674.00
151,460.00
Issuance/Reduction of Debt, Net
166,515.00
2,225.00
288,874.00
29,017.00
8,523.00
Net Financing Cash Flow
313,578.00
210,944.00
303,070.00
4,176.00
19,835.00
Net Change in Cash
60,710.00
1,193.00
187,590.00
207,283.00
71,732.00
Free Cash Flow
282,447.00
159,106.00
110,376.00
29,639.00
103,774.00
Change in Capital Stock
147,063.00
213,169.00
14,196.00
24,841.00
26,370.00

About Ironwood Pharmaceuticals

View Profile
Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.ironwoodpharma.com
Updated 07/08/2019
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.